Will This Price Target Increase Help Teva Pharmaceuticals (TEVA) Stock Today?

Story updated at 10 a.m. to reflect market activity.

NEW YORK (TheStreet) -- UBS raised its price target for Teva Pharmaceuticals (TEVA) to $54 from $50 Monday, reiterating its "neutral" rating.

Shares of Teva fell 0.2% to $53.90 in morning trading.

The analyst firm also raised its EPS estimates for the pharmaceutical company through 2016 due to higher base sales.

"New mgt continues to provide its new strategy going forward, and yet we are still not sure what is really different from the old strategy," UBS analyst Marc Goodman wrote. "The emphasis on more profitable growth in generics and on growth from key therapeutic areas such as pain and respiratory doesn't sound much different from the old strategy. The extra $300M to the bottom line is new from the new mgt and certainly a positive but not a surprise and not an upside to investors given mgt's comments most of the year on this topic."

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

----------------

Separately, TheStreet Ratings team rates TEVA PHARMACEUTICALS as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate TEVA PHARMACEUTICALS (TEVA) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

If you liked this article you might like

CEOs Are Dropping Like Flies

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed